Netherlands-based medical device company, ViCentra, on Thursday said it has closed Series C financing of €65M led by new investor Partners in Equity BV. The round also saw participation from existing investors LSP, INKEF Capital and Health Innovations.
The new funding will help ViCentra accelerate the commercial launch of Kaleido, the world’s smallest and lightest wearable insulin pump. The company also plans to scale its manufacturing operations and prepare for FDA filing. “The commercial launch of the Kaleido system will focus on the Netherlands, France, Germany and the UK, with additional regions targeted in due course,” Frans Cromme, CEO of ViCentra, said.